ViewRay (OTCPK:VRAY.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

VRAY.Q Stoklara Genel Bakış

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. Daha fazla detay

VRAY.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Risk Analizi

Kazançlar son 5 yılda yılda 6.6% oranında azaldı

Anlamlı bir piyasa değeri yok ( $18K )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

1 yıldan az nakit akışı var

ViewRay, Inc. Rakipler

ThermoGenesis Holdings

OTCPK:THMO

US$11.1k

Motus GI Holdings

OTCPK:MOTS

US$7.0

Lucira Health

OTCPK:LHDX.Q

US$4.2k

BIOLASE

OTCPK:BIOL.Q

US$201.3k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti ViewRay
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.0001
52 Haftanın En Yüksek Seviyesi	US$4.96
52 Haftanın En Düşük Seviyesi	US$0.000001
Beta	0.76
11 Aylık Değişim	-98.88%
3 Aylık Değişim	-99.57%
1 Yıllık Değişim	-100.00%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	VRAY.Q	US Medical Equipment	US Pazar
7D	0%	1.5%	2.2%
1Y	-100.0%	20.8%	31.6%

Getiri vs. Endüstri: VRAY.Q geçen yıl % 20.8 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: VRAY.Q geçen yıl % 31.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is VRAY.Q's price volatile compared to industry and market?
VRAY.Q volatility
VRAY.Q Average Weekly Movement	2,748.1%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: VRAY.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: VRAY.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 1401% dan 2748% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2004	295	Paul Ziegler	www.viewray.com

ViewRay, Inc. Temel Bilgiler Özeti

ViewRay'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VRAY.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$18.34k
Kazançlar(TTM)	-US$110.41m
Gelir(TTM)	US$105.86m

0.0x

P/S Oranı

0.0x

F/K Oranı

VRAY.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VRAY.Q gelir tablosu (TTM)
Gelir	US$105.86m
Gelir Maliyeti	US$97.34m
Brüt Kâr	US$8.52m
Diğer Giderler	US$118.94m
Kazançlar	-US$110.41m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.60
Brüt Marj	8.05%
Net Kâr Marjı	-104.30%
Borç/Özkaynak Oranı	140.7%

VRAY.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

VRAY.Q Stoklara Genel Bakış

Risk Analizi

ViewRay, Inc. Rakipler

OTCPK:THMO

US$11.1k

OTCPK:MOTS

US$7.0

OTCPK:LHDX.Q

US$4.2k

OTCPK:BIOL.Q

US$201.3k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021